The biotechnology and pharmaceutical company Glaukos (GKOS), focused on ophthalmic diseases, garnered significant investor attention on Thursday, with its stock price surging nearly 14% during the day. This strong performance starkly contrasted with the overall market trend where the S&P 500 index fell by 1%. The primary drivers behind this surge stemmed from the company’s robust quarterly earnings report and its optimistic outlook for future growth.
In the third quarter, Glaukos delivered exceptional performance, achieving record net sales of $133.5 million, representing a 38% year-over-year increase. The core driver of this growth was the outstanding sales of its glaucoma treatment drugs, whose net sales also reached a record high of $110 million, a significant 45% increase compared to the same period last year. Regarding profitability, the company reported a non-GAAP net loss of $9.2 million for the quarter, or a loss of $0.16 per share. This result shows a significant improvement compared to the net loss of over $15 million in the same period last year and surpassed the general expectations of market analysts. Previously, analysts had on average anticipated third-quarter revenue to be slightly below $122.5 million, with an adjusted net loss as high as $0.26 per share.
CEO Thomas Burns stated in the press release that this performance reflects the continued strong growth momentum of the company’s business, benefiting from the successful global execution of its key strategic initiatives. Based on the strong performance of the current business, Glaukos management has adopted a more positive outlook for the future. The company has raised its full-year net sales guidance for fiscal year 2025 to a new range of $490 million to $495 million, up from the previous expectation of $480 million to $486 million. Furthermore, Glaukos also issued preliminary sales expectations for fiscal year 2026, projecting net sales to reach between $600 million and $620 million. This robust earnings report, coupled with the significantly raised financial guidance, collectively formed the key factors driving the company’s stock price to surge nearly 14% on the day.
